Guidance for the care of neuromuscular ...
Type de document :
Article dans une revue scientifique: Article original
PMID :
URL permanente :
Titre :
Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network.
Auteur(s) :
Solé, G [Auteur]
CHU de Bordeaux Pellegrin [Bordeaux]
Salort-Campana, E [Auteur]
Marseille medical genetics - Centre de génétique médicale de Marseille [MMG]
Pereon, Y [Auteur]
Centre Hospitalier Universitaire de Nantes [CHU Nantes]
Stojkovic, T [Auteur]
Wahbi, K [Auteur]
AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris]
Cintas, P [Auteur]
Adams, D [Auteur]
Service de Neuroradiologie [CHU de Bicêtre]
Laforet, P [Auteur]
CHU Pitié-Salpêtrière [AP-HP]
Tiffreau, Vincent [Auteur]
Unité de Recherche Pluridisciplinaire Sport, Santé, Société (URePSSS) - ULR 7369 - ULR 4488 [URePSSS]
Desguerre, I [Auteur]
Hôpital Necker - Enfants Malades [AP-HP]
Pisella, L I [Auteur]
Hôpital de la Timone [CHU - APHM] [TIMONE]
Molon, A [Auteur]
Hôpital de la Timone [CHU - APHM] [TIMONE]
Attarian, S [Auteur]
Hôpital de la Timone [CHU - APHM] [TIMONE]
CHU de Bordeaux Pellegrin [Bordeaux]
Salort-Campana, E [Auteur]
Marseille medical genetics - Centre de génétique médicale de Marseille [MMG]
Pereon, Y [Auteur]
Centre Hospitalier Universitaire de Nantes [CHU Nantes]
Stojkovic, T [Auteur]
Wahbi, K [Auteur]
AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris]
Cintas, P [Auteur]
Adams, D [Auteur]
Service de Neuroradiologie [CHU de Bicêtre]
Laforet, P [Auteur]
CHU Pitié-Salpêtrière [AP-HP]
Tiffreau, Vincent [Auteur]
Unité de Recherche Pluridisciplinaire Sport, Santé, Société (URePSSS) - ULR 7369 - ULR 4488 [URePSSS]
Desguerre, I [Auteur]
Hôpital Necker - Enfants Malades [AP-HP]
Pisella, L I [Auteur]
Hôpital de la Timone [CHU - APHM] [TIMONE]
Molon, A [Auteur]
Hôpital de la Timone [CHU - APHM] [TIMONE]
Attarian, S [Auteur]
Hôpital de la Timone [CHU - APHM] [TIMONE]
Titre de la revue :
Revue Neurologique
Nom court de la revue :
Rev Neurol (Paris)
Numéro :
176
Pagination :
507-515
Date de publication :
2020-06-01
ISSN :
0035-3787
Mot(s)-clé(s) en anglais :
Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Anti-Bacterial Agents
Antimalarials
Azithromycin
Betacoronavirus
COVID-19
Cardiorespiratory Fitness
Coronavirus Infections
Emergency Treatment
France
Glycogen Storage Disease Type II
Hospitalization
Humans
Hydroxychloroquine
Immune System Diseases
Immunoglobulins, Intravenous
Immunosuppressive Agents
Muscular Atrophy, Spinal
Neuromuscular Diseases
Oligonucleotides
Pandemics
Physical Therapy Modalities
Pneumonia, Viral
Prognosis
RNA, Small Interfering
SARS-CoV-2
Steroids
Withholding Treatment
alpha-Glucosidases
COVID-19
Guidelines
Management
Neuromuscular
Treatment
Angiotensin-Converting Enzyme Inhibitors
Anti-Bacterial Agents
Antimalarials
Azithromycin
Betacoronavirus
COVID-19
Cardiorespiratory Fitness
Coronavirus Infections
Emergency Treatment
France
Glycogen Storage Disease Type II
Hospitalization
Humans
Hydroxychloroquine
Immune System Diseases
Immunoglobulins, Intravenous
Immunosuppressive Agents
Muscular Atrophy, Spinal
Neuromuscular Diseases
Oligonucleotides
Pandemics
Physical Therapy Modalities
Pneumonia, Viral
Prognosis
RNA, Small Interfering
SARS-CoV-2
Steroids
Withholding Treatment
alpha-Glucosidases
COVID-19
Guidelines
Management
Neuromuscular
Treatment
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
In France, the epidemic phase of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began in February 2020 and resulted in the implementation of emergency measures and a degradation in the ...
Lire la suite >In France, the epidemic phase of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began in February 2020 and resulted in the implementation of emergency measures and a degradation in the organization of neuromuscular reference centers. In this special context, the French Rare Health Care for Neuromuscular Diseases Network (FILNEMUS) has established guidance in an attempt to homogenize the management of neuromuscular (NM) patients within the French territory. Hospitalization should be reserved for emergencies, the conduct of treatments that cannot be postponed, check-ups for which the diagnostic delay may result in a loss of survival chance, and cardiorespiratory assessments for which the delay could be detrimental to the patient. A national strategy was adopted during a period of 1 to 2months concerning treatments usually administered in hospitalization. NM patients treated with steroid/immunosuppressants for a dysimmune pathology should continue all of their treatments in the absence of any manifestations suggestive of COVID-19. A frequently asked questions (FAQ) sheet has been compiled and updated on the FILNEMUS website. Various support systems for self-rehabilitation and guided exercises have been also provided on the website. In the context of NM diseases, particular attention must be paid to two experimental COVID-19 treatments, hydroxycholoroquine and azithromycin: risk of exacerbation of myasthenia gravis and QT prolongation in patients with pre-existing cardiac involvement. The unfavorable emergency context related to COVID-19 may specially affect the potential for intensive care admission (ICU) for people with NMD. In order to preserve the fairest medical decision, a multidisciplinary working group has listed the neuromuscular diseases with a good prognosis, usually eligible for resuscitation admission in ICU and, for other NM conditions, the positive criteria suggesting a good prognosis. Adaptation of the use of noninvasive ventilation (NIV) make it possible to limit nebulization and continue using NIV in ventilator-dependent patients.Lire moins >
Lire la suite >In France, the epidemic phase of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began in February 2020 and resulted in the implementation of emergency measures and a degradation in the organization of neuromuscular reference centers. In this special context, the French Rare Health Care for Neuromuscular Diseases Network (FILNEMUS) has established guidance in an attempt to homogenize the management of neuromuscular (NM) patients within the French territory. Hospitalization should be reserved for emergencies, the conduct of treatments that cannot be postponed, check-ups for which the diagnostic delay may result in a loss of survival chance, and cardiorespiratory assessments for which the delay could be detrimental to the patient. A national strategy was adopted during a period of 1 to 2months concerning treatments usually administered in hospitalization. NM patients treated with steroid/immunosuppressants for a dysimmune pathology should continue all of their treatments in the absence of any manifestations suggestive of COVID-19. A frequently asked questions (FAQ) sheet has been compiled and updated on the FILNEMUS website. Various support systems for self-rehabilitation and guided exercises have been also provided on the website. In the context of NM diseases, particular attention must be paid to two experimental COVID-19 treatments, hydroxycholoroquine and azithromycin: risk of exacerbation of myasthenia gravis and QT prolongation in patients with pre-existing cardiac involvement. The unfavorable emergency context related to COVID-19 may specially affect the potential for intensive care admission (ICU) for people with NMD. In order to preserve the fairest medical decision, a multidisciplinary working group has listed the neuromuscular diseases with a good prognosis, usually eligible for resuscitation admission in ICU and, for other NM conditions, the positive criteria suggesting a good prognosis. Adaptation of the use of noninvasive ventilation (NIV) make it possible to limit nebulization and continue using NIV in ventilator-dependent patients.Lire moins >
Comité de lecture :
Oui
Audience :
Non spécifiée
Établissement(s) :
Université de Lille
Univ. Artois
Univ. Littoral Côte d’Opale
Univ. Artois
Univ. Littoral Côte d’Opale
Équipe(s) de recherche :
Activité Physique, Muscle, Santé (APMS)
Date de dépôt :
2021-02-08T18:41:52Z
2021-02-15T08:55:04Z
2021-02-15T08:55:04Z
Fichiers
- 2020_Solé_Rev Neurol.pdf
- Version finale acceptée pour publication (postprint)
- Accès libre
- Accéder au document